A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
Latest Information Update: 18 Apr 2025
At a glance
- Drugs Admilparant (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms ALOFT; ALOFT-IPF
- Sponsors Bristol-Myers Squibb
- 13 Jan 2025 Trial design presented at 43rd Annual J.P. Morgan Healthcare Conference and data from this trial is expected in 2026.
- 25 Sep 2023 Status changed from not yet recruiting to recruiting.
- 15 Aug 2023 Status changed from planning to not yet recruiting.